Pharma BD Deal Intelligence
A $2.9B Novartis licensing deal for PTC518 (votoplam), an oral Huntington's disease splicing modifier, with $1B upfront and a $50M milestone triggered by Phase 3 dosing. Phase 3 INVEST-HD is now underway, backed by PIVOT-HD interim data showing dose-dependent slowing of disease progression (52% at 10mg).
Phase 3 INVEST-HD: randomized, placebo-controlled study of votoplam in Huntington's disease; sponsor Novartis; ~770 participants; start 2026-03-24; primary…
Month-24 PIVOT-HD LTE: dose-dependent slowing on cUHDRS in Stage 2 HD (52% at 10mg, 28% at 5mg) vs natural-history cohort; votoplam = former PTC518.
First patient dosed in Phase 3 INVEST-HD study, triggering $50 million milestone payment from Novartis to PTC in Q2 2026.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Novartis licensed PTC518 (now votoplam), an oral small-molecule HTT-lowering splicing modifier for Huntington's disease then in Phase II, paying $1B upfront in a deal worth up to $2.9B. The license closed March 31, 2025, after which Novartis assumed development, manufacturing and commercialization. Novartis advanced the program into the global Phase 3 INVEST-HD study (~770 early HD patients, cUHDRS at Month 36), dosing its first patient in Q2 2026 and triggering a $50M milestone payment to PTC. Phase 3 was supported by the Month-24 PIVOT-HD long-term-extension interim, which showed dose-dependent slowing of disease progression on cUHDRS (52% at 10mg, 28% at 5mg) vs. natural-history controls.
Huntington's disease (HD) has no disease-modifying therapy approved; PTC518 is an oral HTT-lowering splice modulator entering a field of failed prior candidates. Oral HTT splice modulators (PTC518's direct MOA): PTC Therapeutics' PTC518 (Phase 2 PIVOT-HD, 12-month data showed dose-dependent HTT lowering in blood/CSF) is first-in-class oral; no direct oral competitor at equivalent stage. Intrathecal antisense oligonucleotides (ASO — adjacent MOA): Roche/Ionis's tominersen (RG6042/IONIS-HTTRx, Phase 3 GENERATION HD1 halted 2021 for futility/harm, relaunched GENERATION HD2 Phase 2 2022 in lower-burden patients); Wave Life Sciences' WVE-003 (SNP3 allele-selective, Phase 1b/2a SELECT-HD showing mHTT lowering). RNAi/gene therapy (one-time intraparenchymal — adjacent MOA): uniQure's AMT-130 (AAV5-miRNA, Phase 1/2 showing slower disease progression in high-dose cohort, 2024 interim update) is the lead gene therapy; Spark/Roche and Voyager had earlier programs. Symptomatic/chorea SOC (incumbent): Teva's Austedo (deutetrabenazine, VMAT2 inhibitor, approximately $1.6B 2024 sales across HD chorea and tardive dyskinesia) and Lundbeck/Bausch's Ingrezza/Xenazine (valbenazine/tetrabenazine, VMAT2) manage chorea only. Antipsychotics and SSRIs are used off-label for psychiatric symptoms. For a commercial lead, PTC518's oral administration is a major commercial differentiator vs. intrathecal tominersen or AAV-delivered AMT-130 — Novartis's $2.9B bet prices in category leadership if Phase 3 establishes disease modification.
Novartis paid $1B upfront for PTC518 (Phase II HTT lowering agent). Up to $1.9B in milestones.
PTC518 showed dose-dependent HTT reduction: 23% at 5mg, 39% at 10mg. Clinical benefit signals in Stage 2 patients.
Novartis initiated the global Phase 3 INVEST-HD study of votoplam (formerly PTC518) in early Huntington's disease: ~770 patients, oral 10mg vs placebo (3:2), primary endpoint cUHDRS change at Month 36.
PTC reported positive Month-24 PIVOT-HD long-term-extension interim: dose-dependent slowing on cUHDRS (52% at 10mg, 28% at 5mg) vs natural-history controls in Stage 2 HD.
First patient dosed in Phase 3 INVEST-HD triggered a $50M milestone payment from Novartis to PTC, expected Q2 2026.
Novartis planning Phase 3 based on positive Phase 2 results. $1B upfront reflects high conviction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / PTC Therapeutics Inc. (this deal) | 2024 | $2.9B | 80 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Neurology deals